FDA turns down high doses of Merck's insomnia drug suvorexant

07/3/2013 | Zacks · MedPage Today (free registration)

Merck failed to obtain the FDA's approval for higher doses of its experimental insomnia drug suvorexant. The agency sent Merck a complete-response letter saying that safety data don't support the approval of 30- and 40-milligram doses. A 10-milligram dose of suvorexant should be the starting dose for the majority of patients, the FDA said.

View Full Article in:

Zacks · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC